QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:BDSX

Biodesix (BDSX) Stock Forecast, Price & News

$1.49
-0.05 (-3.25%)
(As of 09/28/2023 ET)
Compare
Today's Range
$1.47
$1.52
50-Day Range
$1.04
$1.74
52-Week Range
$0.96
$2.53
Volume
15,568 shs
Average Volume
85,178 shs
Market Capitalization
$117.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Biodesix MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Biodesix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$203,017 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.66) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

892nd out of 969 stocks

Medical Laboratories Industry

22nd out of 25 stocks


BDSX stock logo

About Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

BDSX Price History

BDSX Stock News Headlines

Jack Schuler Spends US$217k On Biodesix Stock
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Jack Schuler Spends US$65k On Biodesix Stock \
See More Headlines
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Company Calendar

Last Earnings
8/07/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDSX
Fax
N/A
Employees
245
Year Founded
N/A

Profitability

Net Income
$-65,450,000.00
Net Margins
-158.72%
Pretax Margin
-158.72%

Debt

Sales & Book Value

Annual Sales
$38.21 million
Book Value
$0.27 per share

Miscellaneous

Free Float
28,458,000
Market Cap
$121.06 million
Optionable
Not Optionable
Beta
1.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Scott HuttonMr. Scott Hutton (Age 51)
    Pres, CEO & Director
    Comp: $632k
  • Ms. Robin Harper CowieMs. Robin Harper Cowie (Age 43)
    CFO, Sec. & Treasurer
    Comp: $390.87k
  • Dr. Heinrich Röder
    Founder & CTO
  • Mr. Christopher Vazquez
    VP, Controller & Chief Accounting Officer
  • Mr. Jeffrey A. Bojar
    VP of Legal and Regulatory Affairs
  • Mr. Mark DeBlock
    VP of Sales
  • Mr. Robbie Lunt
    Sr. Director of Marketing
  • Ms. Molli Halvorson
    Director of HR
  • Dr. Gary Anthony Pestano Ph.D. (Age 56)
    Chief Devel. Officer
  • Ms. Bobbi Coffin
    Chief Growth Officer













BDSX Stock - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings
or view top-rated stocks.

How have BDSX shares performed in 2023?

Biodesix's stock was trading at $2.30 at the start of the year. Since then, BDSX stock has decreased by 33.0% and is now trading at $1.54.
View the best growth stocks for 2023 here
.

Are investors shorting Biodesix?

Biodesix saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 229,600 shares, an increase of 27.1% from the August 31st total of 180,700 shares. Based on an average daily trading volume, of 68,400 shares, the short-interest ratio is currently 3.4 days. Currently, 2.0% of the company's shares are short sold.
View Biodesix's Short Interest
.

When is Biodesix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BDSX earnings forecast
.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) released its earnings results on Monday, August, 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm earned $11.87 million during the quarter, compared to analysts' expectations of $11.38 million. Biodesix had a negative trailing twelve-month return on equity of 1,628.23% and a negative net margin of 158.72%.

What guidance has Biodesix issued on next quarter's earnings?

Biodesix updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $52.00 million-$55.00 million, compared to the consensus revenue estimate of $53.18 million.

When did Biodesix IPO?

(BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Biodesix's stock symbol?

Biodesix trades on the NASDAQ under the ticker symbol "BDSX."

Who are Biodesix's major shareholders?

Biodesix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (1.61%), Wells Fargo & Company MN (1.07%), BlackRock Inc. (0.52%), Geode Capital Management LLC (0.47%), Legato Capital Management LLC (0.45%) and State Street Corp (0.35%). Insiders that own company stock include Charles M Watts, Chris Vazquez, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton.
View institutional ownership trends
.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biodesix's stock price today?

One share of BDSX stock can currently be purchased for approximately $1.54.

How much money does Biodesix make?

Biodesix (NASDAQ:BDSX) has a market capitalization of $121.06 million and generates $38.21 million in revenue each year. The company earns $-65,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Biodesix have?

The company employs 245 workers across the globe.

How can I contact Biodesix?

The official website for the company is www.biodesix.com. The company can be reached via phone at 303-417-0500 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:BDSX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -